European Multicentre Study of Long-term Results Following Visceral Arteries Revascularization: the E-VisAR Study

Launched by AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA · Mar 30, 2025

Keywords

ClinConnect Summary

The E-VisAR Study is a clinical trial that aims to understand the long-term outcomes of treatments for diseases affecting visceral arteries, which are blood vessels that supply important organs like the stomach and kidneys. Specifically, the study will compare two types of treatment: endovascular revascularization (a less invasive method using small tubes) and open surgical repair (a more traditional surgical approach). The goal is to see which method leads to better survival rates over time, particularly focusing on how patients fare five years and beyond after their treatment.

To participate in this study, patients must have conditions such as artery blockages, aneurysms, or dissections affecting one or more of the visceral arteries. The study is open to all patients aged 65 and older who have received revascularization treatment, whether in emergency situations or planned surgeries. During the study, participants will be followed over time to gather important information about their health outcomes. This trial is significant because it seeks to fill gaps in knowledge regarding long-term treatment effectiveness for these rare but serious conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients presenting with atherosclerotic disease, aneurysms, or dissection;
• • Pathologies involving one or more visceral vessels (celiac, mesenteric, renal arteries, and their branches);
• • Patients receiving revascularization, both surgical and endovascular, in elective and urgent/emergent settings;
• • For the retrospective cohort, patients who underwent revascularization up to 20 years from the study launch regardless of the follow-up time.
• Exclusion Criteria:
• • Absence of follow-up imaging available and/or reported in follow-up medical reports;
• • For the retrospective cohort, a follow-up shorter than three years.